Comorbidity Indices Predict Survival Among Elderly Patients with Acute Myelogenous Leukemia but Do Not Aid in Selecting Between Traditional Induction Chemotherapy and 5-Azacytidine Treatment.

@inproceedings{Goldberg2009ComorbidityIP,
  title={Comorbidity Indices Predict Survival Among Elderly Patients with Acute Myelogenous Leukemia but Do Not Aid in Selecting Between Traditional Induction Chemotherapy and 5-Azacytidine Treatment.},
  author={Stuart L Goldberg and Aisha Masood and Jayshree M. Shah and Jack W. Hsu and Neelesh Rastogi and Kevin Lu and Genique Stanislaus and Ken Granholm and Elizabeth Tyler Jones and Sora Limor and Jimmy L Nieves and Alyona Weinstein and William Alejandro Berm{\'u}dez Marrero and A Loza Vargas and Sara Hyman and Yesenia Llerena and Michelle Hanrahan and Jamie L Yaniga},
  year={2009}
}
Abstract 1040 Poster Board I-62 Treatment of the elderly patient with acute myelogenous leukemia remains problematic as many have poor performance status precluding aggressive therapy and others have high risk features including abnormal cytogenetics. The success of 5-azacitidine among patients with advanced myelodysplastic syndromes in controlling blast cells and prolonging survival has led to its use in AML. However choosing between potentially curative hospital-based induction chemotherapy… CONTINUE READING

Topics from this paper.

Similar Papers

Loading similar papers…